PubMed for id: 2444

Year	Number of Results
1993	1
1994	2
1995	1
1999	1
2002	1
2003	4
2004	2
2005	1
2008	1
2009	2
2010	3
2011	4
2012	5
2013	7
2014	7
2015	4
2016	1
2017	3
2018	2
2019	4
2020	8
2021	2
2022	2
2023	2
2024	0

1

FRK suppresses human glioma growth by inhibiting ITGB1/FAK signaling.

Wang J, Cai C, Nie D, Song X, Sun G, Zhi T, Li B, Qi J, Zhang J, Chen H, Shi Q, Yu R. Wang J, et al. Biochem Biophys Res Commun. 2019 Oct 1;517(4):588-595. doi: 10.1016/j.bbrc.2019.07.059. Epub 2019 Aug 5. Biochem Biophys Res Commun. 2019. PMID: 31395336

2

FRK plays an oncogenic role in non-small cell lung cancer by enhancing the stemness phenotype via induction of metabolic reprogramming.

Zhang L, Yang Y, Chai L, Bu H, Yang Y, Huang H, Ran J, Zhu Y, Li L, Chen F, Li W. Zhang L, et al. Int J Cancer. 2020 Jan 1;146(1):208-222. doi: 10.1002/ijc.32530. Epub 2019 Jul 26. Int J Cancer. 2020. PMID: 31251822 Free article.

3

Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma.

Hu G, Dasari S, Asmann YW, Greipp PT, Knudson RA, Benson HK, Li Y, Eckloff BW, Jen J, Link BK, Jiang L, Sidhu JS, Wellik LE, Witzig TE, Bennani NN, Cerhan JR, Boddicker RL, Feldman AL. Hu G, et al. Leukemia. 2018 Feb;32(2):565-569. doi: 10.1038/leu.2017.309. Epub 2017 Oct 13. Leukemia. 2018. PMID: 29026208 Free PMC article. No abstract available.

4

Repression of Fyn-related kinase in breast cancer cells is associated with promoter site-specific CpG methylation.

Bagu ET, Miah S, Dai C, Spriggs T, Ogunbolude Y, Beaton E, Sanders M, Goel RK, Bonham K, Lukong KE. Bagu ET, et al. Oncotarget. 2017 Feb 14;8(7):11442-11459. doi: 10.18632/oncotarget.14546. Oncotarget. 2017. PMID: 28077797 Free PMC article.

5

Zhang X, Li F, Zhu PL. Zhang X, et al. Biomed Pharmacother. 2016 Dec;84:270-276. doi: 10.1016/j.biopha.2016.09.042. Epub 2016 Sep 22. Biomed Pharmacother. 2016. PMID: 27665472

6

FRK inhibits migration and invasion of human glioma cells by promoting N-cadherin/β-catenin complex formation.

Shi Q, Song X, Wang J, Gu J, Zhang W, Hu J, Zhou X, Yu R. Shi Q, et al. J Mol Neurosci. 2015 Jan;55(1):32-41. doi: 10.1007/s12031-014-0355-y. Epub 2014 Jun 27. J Mol Neurosci. 2015. PMID: 24969324

7

Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation.

Pilati C, Letouzé E, Nault JC, Imbeaud S, Boulai A, Calderaro J, Poussin K, Franconi A, Couchy G, Morcrette G, Mallet M, Taouji S, Balabaud C, Terris B, Canal F, Paradis V, Scoazec JY, de Muret A, Guettier C, Bioulac-Sage P, Chevet E, Calvo F, Zucman-Rossi J. Pilati C, et al. Cancer Cell. 2014 Apr 14;25(4):428-41. doi: 10.1016/j.ccr.2014.03.005. Cancer Cell. 2014. PMID: 24735922 Free article.

8

In silico identification of oncogenic potential of fyn-related kinase in hepatocellular carcinoma.

Chen JS, Hung WS, Chan HH, Tsai SJ, Sun HS. Chen JS, et al. Bioinformatics. 2013 Feb 15;29(4):420-7. doi: 10.1093/bioinformatics/bts715. Epub 2012 Dec 24. Bioinformatics. 2013. PMID: 23267173

9

FRK controls migration and invasion of human glioma cells by regulating JNK/c-Jun signaling.

Zhou X, Hua L, Zhang W, Zhu M, Shi Q, Li F, Zhang L, Song C, Yu R. Zhou X, et al. J Neurooncol. 2012 Oct;110(1):9-19. doi: 10.1007/s11060-012-0933-1. Epub 2012 Jul 13. J Neurooncol. 2012. PMID: 22790444

10

Mutation analysis of the FRK gene in non-small cell lung cancers.

Jin G, Jeon HS, Yang E, Park JY. Jin G, et al. Lung Cancer. 2011 Jan;71(1):115-7. doi: 10.1016/j.lungcan.2010.10.002. Epub 2010 Nov 11. Lung Cancer. 2011. PMID: 21074287 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

60 results

Results by year